Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity

Molecular Pharmacology

Volumn 52, Issue 1, 1997, Pages 155-163

  Galpin, Amy J ^a   Schuetz, John D ^a,b   Masson, Eric ^a   Yanishevski, Yuri ^a   Synold, Timothy W ^a   Barredo, Julio C ^c   Pui, Ching Hon ^a,b   Relling, Mary V ^a,b   Evans, William E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHASE; MESSENGER RNA; METHOTREXATE; METHOTREXATE POLYGLUTAMATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CELL CYCLE S PHASE; CHILD; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOBLAST; MAJOR CLINICAL STUDY; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 0030756226     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.1.155     Document Type: Article

References (40)

1. Chabner, B. A., C. J. Allegra, G. A. Curt, N. J. Clendeninn, J. Baram, S. Koizumi, J. C. Drake, and J. Jolivet. Polyglutamation of methotrexate: is methotrexate a prodrug? J. Clin. Invest. 76:907 (1985).
2. Shane, B. L. The role of folylpolyglutamate synthase in the regulation of folate and one-carbon metabolism. Vitam. Horm. 46:263 (1989).
3. Jolivet, J., R. L. Schilsky, B. A. D. Bailey, J. C. Drake, and B. A. Chabner. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J. Clin. Invest. 70:351 (1982).
4. Fry, D. W., J. C. Yalowich, and I. D. Goldman. Rapid formation of poly-γ-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high-pressure liquid chromatography in Ehrlich ascites tumor cell in vitro. J. Biol. Chem, 259:257 (1982).
5. Allegra, C. J., J. C. Drake, J. Jolivet, and B. A. Chabner. Inhibition of phosphoribosylamino-imidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA 82:4881 (1985).
6. McCloskey, D. E., J. J. McGuire, C. A. Russell, B. G. Rowan, J. R. Bertino, G. Pizzorno, and E. Mini. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol Chem. 266:6181 (1991).
7. Cowan, K. H., and J. Jolivet. A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J. Biol. Chem. 259:10793 (1984).
8. Pizzorno, G., Y.-M. Chang, J. J. McGuire, and J. R. Bertino. Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res. 49:5272 (1989).
9. Matherly, L. H., J. W. Taub, Y. Ravindranath, S. A. Proefke, S. C. Wong, P. Gimotty, and S. Buck. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85:500 (1995).
10. Li, W.-W., J. T. Lin, W. P. Tong, T. M. Trippett, M. F. Brennan, and J. R. Bertino. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res. 52:1434 (1992).
11. Fahre, I., G. Fahre, and I. D. Goldman. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res. 44:3190 (1984).
12. Schuetz, J. D., E. H. Westin, L. H. Matherly, R. Pineus, P. S. Swerdlow, and I. D. Goldman. Membrane protein changes in an L1210 leukemia cell line with a translocation defect in the methotrexate-tetrahydrofolate cofactor transport courier. J. Biol. Chem. 264:16261 (1989).
13. Srimatkandada, S., B. I. Schweitzer, B. A. Moroson, S. Dube, and J. R. Bertino. Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J. Biol. Chem. 264:3524 (1989).
14. Alt, F. W., R. E. Kellems, J. R. Bertino, and R. T. Schimke. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol. Chem. 253:1357 (1978).
15. Wang, Y., J. A. Dias, Z. Nimec, R. Rotundo, B. M. O'Connor, J. Freisheim, and J. Galivan. The properties and function of gamma-glutamyl hydrolase and poly-gamma-glutamate. Adv. Enzyme Regul. 33:207 (1993).
16. Goker, E., J. T. Lin, T. Trippett, Y. Elisseyeff, W. P. Tong, D. Niedzwiecki, C. Tan, P. Steinherz, B. I. Schweitzer, and J. R. Bertino. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts . in adults compared to children with this disease. Leukemia 7:1000 (1993).
17. Whitehead, V. M., M. J. Vuchich, S. J. Lauer, D. Mahoney, A. J. Carroll, J. J. Shuster, and D. J. Pullen. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 80:1316 (1992).
18. Synold, T. W., M. V. Relling, J. M. Boyett, G. K. Rivera, J. T. Sandlund, H. Mahmoud, W. M. Crist, C.-H. Pui, and W. E. Evans. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest. 94: 1996 (1994).
19. Barredo, J. C., T. W. Synold, J. Laver, M. V. Relling, C.-H. Pui, D. G. Priest, and W. E. Evans. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84:564 (1994).
20. Masson, E., M. V. Relling, T. W. Synold, Q. Liu, J. D. Schuetz, J. T. [ Sandlund, C.-H. Pui, and W. E. Evans. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: a rationale for high-dose methotrexate. J. Clin Invest. 97:73 (1996).
21. Matherly, L. H., J. D. Schuetz, E. Westin, and I. D. Goldman. A method for the synchronization of cultured cells with aphidicolin: application to the large-scale synchronization of L1210 cells and the study of the cell cycle regulation of thymidylate synthase and dihydrofolate reductase. Anal. Biochem. 182:338 (1989).
22. Garrow, T. A., A. Admon, and B. Shane. Expression cloning of a human cDNA encoding folylpoly(gamma-glutamate) synthetase and determination of its primary structure. Proc. Natl. Acad. Sci. USA 89:9151 (1992).
23. Schuetz, J. D., S. Kauma, and P. S. Guzelian. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J. Clin. Invest. 42:1018 (1993).
24. Antonsson, B., J. Barredo, and R. G. Moran. A microassay for mammalian folylpolyglutamate synthetase. Anal. Biochem. 186:8 (1990).
25. Kamen, B. A., and N. Winick. Analysis of methotrexate polyglutamate derivatives in vivo. Methods Enzymol. 122:339 (1986).
26. Hurwitz, R., J. Hozier, T. LeBien, J. Minowada, K. Gajl-Peczalska, I. Kubonishi, and J. Kersey. Characterization of a leukemia cell line of the Pre-B phenotype. Int. J. Cancer 23:174 (1979).
27. Campana, D., A. Manabe, and W. E. Evans. Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs. Leukemia 7:482 (1993).
28. DeLean, A., P. J. Munson, and D. Rodbord. Simultaneous analysis of families of sigmoid curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235:E97 (1978).
29. Chomcynski, P., and N. Sacchi. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156 (1987).
30. Schuetz, J. D., D. L. Beach, and P. S. Guzelian. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11 (1994).
31. Schuetz, J. D., K. M. Gorse, I. D. Goldman, and E. H. Westin. Transient inhibition of DNA synthesis by 5-fluorodeoxvuridine leads to overexpression of dihydrofolate reductase with increased frequency of methotrexate resistance. J. Biol. Chem. 263:7708 (1988).
32. Pui, C.-H., F. G. Behm, and W. M. Crist. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82:343 (1993).
33. Rivera, G. K., S. C. Raimondi, M. L. Hancock, F. G. Behm, C.-H. Pui, M. Abromowitch, J. Mirro, J. S. Ochs, A. T. Look, D. L. Williams, S. B. Murphy, G. V. Dahl, D. K. Kalwinsky, W. E. Evans, L. E. Kun, J. V. Simone, and W. M. Crist. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61 (1991).
34. Moran, R. G., and P. D. Colman. Measurement of folylpolyglutamate synthetase in mammalian tissues. Anal. Biochem. 140:326 (1984).
35. Barredo, J., and R. G. Moran. Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development. Mol. Pharmacol. 42:687 (1992).
36. Fort, D. W., R. H. Lark, A. K. Smith, M. Marling-Cason, S. D. Weitman, B. Shane, and B. A. Kamen. Accumulation of 5-methyltetrahydrofolic acid and folylpolyglutamate synthetase expression by mitogen stimulated hu-man lymphocytes. Br. J. Haematol. 84:595 (1993).
37. 14C)-formate incorporation into nucleic acids and proteins. Mol. Pharmacol. 11:287 (1975).
38. Relling, M. V., D. Fairclough, D. Ayers, W. R. Crom, J. H. Rodman, C.-H. Pui, and W. E. Evans. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J. Clin. Oncol. 12:1667 (1994).
39. Reiter, A., M. Schrappe, W. D. Ludwig, W. Hiddemann, S. Sauter, G. Henze, M. Zimmerman, F. Lampert, W. Havers, D. Niethammer, E. Odenwald, J. Ritter, G. Mann, K. Weite, H. Gadner, and H. Riehm. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 84: 3122 (1994).
40. Evans, W. E., W. R. Crom, M. Abromowitch, R. Dodge, A. T. Look, W. P. Bowman, S. L. George, and C.-H. Pui. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med. 314:471 (1986).